Effect of anti-IL-2-receptor monoclonal antibody BT 563 in treatment of acute interstitial renal rejection.
Carl
S
S
Department of Urology, University of Heidelberg, Germany.
Wiesel
M
M
Daniel
V
V
Staehler
G
G
D000208:Acute Disease; D000328:Adult; D000911:Antibodies, Monoclonal / Q000097:blood / Q000627:therapeutic use*; D015703:Antigens, CD / Q000097:blood; D001379:Azathioprine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D016572:Cyclosporine / Q000627:therapeutic use; D004797:Enzyme-Linked Immunosorbent Assay; D006084:Graft Rejection / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D016030:Kidney Transplantation / Q000276:immunology*; D008775:Methylprednisolone / Q000627:therapeutic use; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D016176:T-Lymphocyte Subsets / Q000276:immunology
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D015375:Receptors, Interleukin-2; D016572:Cyclosporine; C079843:inolimomab; D001379:Azathioprine; D008775:Methylprednisolone